Completed

Phase 3
Age: 38Years - 86Years
FEMALE
ID00000555

Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2016-07-12

N/A

Participants Needed

N/A

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

To assess whether hormonal replacement therapy and/or antioxidant treatment would stabilize or inhibit progression, and induce regression of coronary plaques. The mechanisms by which these treatments modified atherosclerosis in women were also explored.

CONDITIONS

Official Title

Women's Angiographic Vitamin and Estrogen Trial (WAVE)

Who Can Participate

Age: 38Years - 86Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

Postmenopausal women, up to age 86, with angiographically documented coronary artery disease of at least 15 percent, but no more than 75 percent occlusion.

Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

Trial Site Locations

Site Locations not provided

Location information for this trial is currently unavailable.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

FACTORIAL

Primary Purpose

PREVENTION

Number of Arms

0

Similar Trials

Multifactorial Risk Stratification in Acute and Chronic Card...

Cardiovascular Diseases

Actively Recruiting

2 locations

Beneficial Effects of Perfect Heartio Drink in Improving Car...

Cardiovascular Diseases

Actively Recruiting

1 location

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.

David D Waters, Edwin L Alderman, Judith Hsia...

https://pubmed.ncbi.nlm.nih.gov/12435256

Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance.

Barbara V Howard, Judith Hsia, Pamela Ouyang...

https://pubmed.ncbi.nlm.nih.gov/15226212

The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women.

Andrew P Levy, Paula Friedenberg, Rachel Lotan...

https://pubmed.ncbi.nlm.nih.gov/15047650

Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: the Women's Angiographic Vitamin & Estrogen Trial.

Vera Bittner, Mark Tripputi, Judith Hsia...

https://pubmed.ncbi.nlm.nih.gov/15308999

Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial.

Mark Kelemen, Dhananjay Vaidya, David D Waters...

https://pubmed.ncbi.nlm.nih.gov/15721027

Usefulness of serum endothelin levels in predicting death and myocardial infarction but not coronary progression in postmenopausal women with coronary disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study).

Bernice Ruo, Mark T Tripputi, Priscilla Y Hsue...

https://pubmed.ncbi.nlm.nih.gov/16054453